Modern aspects of therapeutic tactics of patients with acantholytic pemphigus
About the author:	A.E-S.E-S. Abdalla	
Heading	RESEARCH VIEW	
Type of article	REVIEW	
Annotation	The article provides an overview of the scientific and medical literature of modern 
methods of treatment of patients with acantholytic pemphigus. Examples of biological, 
antiviral, immunological, extracorporeal, local and other therapy of foreign and domestic
 colleagues are given	
Tags	acantholytic pemphigus, systemic glucocorticosteroids, basic therapy, adjuvant therapy, 
local therapy	
Bibliography	•	1.  1,Adaskevich VP, Kozlovskaya VV. Puzyrchatka: epidemiologiya, patogenez, klinicheskiye proyavleniya, diagnostika [Pemphigus: epidemiology, pathogenesis, clinical manifestations, diagnosis]. 
Medicinskie novosti (Minsk). 2008;16:14–9. 
2.  Baltabaev  MK,  Baltabaev  AM.  Sposob  laboratornoj  diagnostiki  istinnoj  akantoliticheskoj puzyrchatki [A method for laboratory diagnosis of true acantholytic pemphigus]. Patent na izobretenie № 383 ot 30.01.2015 goda. Intellektualdyk menchik (Intellektualnaya sobstvennost). Oficialnyj byulleten, Bishkek, 2015; 1.
3.  Borovskij EV, Mashkilejsona AL. Zabolevaniya slizistoj obolochki polosti rta i gub. Prakticheskoe rukovodstvo [Diseases of the oral mucosa and lips]. M.: MEDpress, 2001; 182–183.
4.  Wolff  K,  Goldsmith  LA,  Katz  SI,  et  al.  Dermatologiya  Fitspatrika  v  klinicheskoy  praktike [Fitzpatrick’s dermatology in general medicine]: v 3 t. Per. s angl.; obshh. red. akad. A. A. Kubanovoj. M.: Izdatel’stvo Panfilova; BINOM. Laboratorija znanij. 2012;1;487–565.
5.  Kalamkaryan  AA,  Trofimova  LYa,  Khapilova VI.  Immunodepressanty  v  kompleksnoy  terapii  puzyrchatki  [Immunosuppressants  in  the  treatment  of  pemphigus].  Vestn  Dermatol  Venerеol. 1979;12:28–32.
6.  Kil’dyushevskiy AV, Molochkov VA, Karzanov OV. Dinamika kletochnogo immuniteta v protsesse ekstrakorporal’noy fotokhimioterapii u bol’nykh istinnoy puzyrchatkoy [The dynamics of cellular immunity in the process of extracorporeal photochemotherapy in patients with true pemphigus]. Rus J Skin Sex Transmit Dis. 2008;4:71–76.
7.  Kubanov AA, Znamenskaya LF, Abramova TV, Svishchenko SI. K voprosam diagnostiki istinnoy (akantoliticheskoy) puzyrchatki [Revisited diagnostics of true (acantholytic) pemphigus]. Vestnik Dermatologii i Venerologii. 2014;6:121–130.
8.  Kubanova AA, Samsonov VA, Khapilova VI, Matushevskaya EV. Sandimmun v terapii bol’nykh istinnoy puzyrchatkoy [Sandimmune in the treatment patients of true pemphigus]. Vestn Dermatol 
Venerol. 1994;6:42.
9.  Lukinih LM. Zabolevaniya slizistoi obolochki polosti rta [Oral mucosal diseases]. Nijnii Novgorod, 2000. 367 р.
10.  Maksimova EM, FMSAl-Asfari, Mihalchenko AV. Ispolzovanie mestnih ranozajivlyayuschih sredstv v terapii erozivnih porajenii slizistoi obolochki polosti rta pri vulgarnoi puzirchatke [The use of local wound healing agents in the treatment of erosive lesions of the oral mucosa with pemphigus vulgaris]. Vestnik Volgogradskogo gosudarstvennogo medicinskogo universiteta. 2017;3(63):71–74.
11.  Matushevskaya  EV,  Kubanova  AA,  Samsonov  VA,  et  al.  Autoantitela  i  autoantigeny  pri puzyrchatke i pemfigoide [Autoantibodies and autoantigens with pemphigus and pemphigoid]. Vestn Dermatol Venerol. 1995;5:28–33.
12.  Matushevskaya  EV,  Svirshchevskaya  EV,  Kubanova  AA,  et  al.  Immunologiya  vul’garnoy puzyrchatki  i  vozmozhnyy  mekhanizm  formirovaniya  zabolevaniya  [Immunology  of  vulgar  pemphigus and a possible mechanism for the formation of the disease]. Vestn Dermatol Venereol. 1996;2:25–28.
13.  Mahneva NV. Kliniko-morfologicheskie i immunologicheskie aspekti v rannei diagnostike i lechenii autoimmunnih bulleznih dermatozov [Clinical, morphological and immunological aspects in the 
early diagnosis and treatment of autoimmune bullous dermatoses]. Avtoref. Diss. dokt. med. nauk. Moscow, 2009; 55. 
14.  Rabinovich OF, Rabinovich IM, Razjivina NV. Puzirchatka slizistoi obolochki rta [Pemphigus oral mucosa]. Parodontologiya. 006(37);1:34.
15.  Samcov  AV,  Belousova  IE.  Bullyoznye  dermatozy  [Bullous  dermatoses].  SPb.:  KOSTA, 2012. 144 p 9. 
•	16.  Sokolovskij EV. Puzyrnye dermatozy. Psoriaz. Sovremennye metody lecheniya [Bullous dermatoses. Psoriasis. Modern treatments]. Seriya «Biblioteka vrachadermatovenerologa». Vypusk 3: 
SPb: SOTIS, 1999; 134 p.
17.  Tkachenko SB, Teplyuk NP, Allenova AS, Lepehova AA. K voprosu o klassifikacii bulleznih dermatozov [On the classification of bullous dermatoses]. Rossiiskii jurnal kojnih i venericheskih boleznei. 2015;18(2):11–14.
18.  Tolmacheva SM, Jdanova ML, Tiunova NV. Klinicheskii sluchai akantoliticheskoi puzirchatki v praktike vracha stomatologa [A clinical case of acantholytic pemphigus in the practice of a dentist]. Dental Forum. 2015;4:86.
19.  Hamaganova IV, Malyarenko EN, Vasileva AYu, et al. Oshibki v diagnostike vulgarnoj puzyrchatki [Mistakes  in  the  diagnosis  of  pemphigus  vulgaris].  Problemy  sovremennoj  nauki  i  obrazovaniya. 2016;8:149–151.
20.  Chebotarev VV, Bajda AP. Rukovodstvo dlya vrachej obshej praktiki (semejnyh vrachej) po dermatovenerologii. Stavropol, 2009. 164 p.
21.  Chebotarev VV,  Sirak  AG,  F.M.S.Al-Asfari,  Sirak V. Obyknovennaya  puzyrchatka:  osobennosti terapii v polosti rta [Pemphigus vulgaris: features of oral therapy]. Medicinskij vestnik Severnogo Kavkaza. 2014;3:215–217.
22.  Chistyakova IA, Lapina EYu. Rol svoevremennoj diagnostiki vulgarnoj puzyrchatki, nachinayushejsya so slizistoj obolochki polosti rta [The role of timely diagnosis of vulgar pemphigus, starting with the oral mucosa]. Vestnik poslediplomnogo medicinskogo obrazovaniya. 2012;2:11–14.
23.  Browning JL. B cells move to centre stage: novel opportunities for autoimmune disease treatment. Nat Rev Drug Discov. 2006;5:564–576.
24.  Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris whit the tumor necrosis factor alpha antagonist etanercept. Cutis. 2014;74(4):245–247.
25.  Bystryn JC, Jiao D. IVIg selectively and rapidly decreases circulating pathogenic autoantibodies in pemphigus vulgaris. Autoimmunity. 2006;39(7):601–607.
26.  Camerlingo C, Portaccio M, Lepore M, Tatе R, Delfino I. Fructose and pectin detection in fruitbased food products by surface-enhanced raman spectroscopy Sensors. 2017;17(4):839–842.
27.  Cianchini G, Lupi F, Masini C, еt al. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. J Am Acad Dermatol. 2012;67(4):617–622.
28.  Craythorne EE, Mufti G, DuVivier AW. Rituximab used as a first-line single agent in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2011;65:1064–1065.
29.  Fellner MJ, Sapadin AN. Current therapy of pemphigus vulgaris. Mt. Sinai J. Med. 2016;68:268–278.
30.  Gürcan HM, Jeph S, Ahmed AR. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. Am J Clin Dermatol. 
2010;11(5):315–326.
31.  Hawayek L, Mutasim D. Pemphigus vulgaris. xPharm Online Pharmacology Reference and Database. Elsevier Science. 2004; http: //www. xpharm.com.
32.  Iraji F, Faghihi G, Siadat AH. The efficacy of acyclovir in treatment of the pemphigus vulgaris. J Res Med Sci. 2013 Nov; 18(11):976–978.
33.  Jan A, Ahmad W, Basit S, et al. A novel homozygous variant in the dsp gene underlies the first case of non-syndromic form of alopecia. Archives of Dermatological Research. 2015;307(9):793–801.
34.  Kanwar  AJ,  Vinay  K. Rituximab  in  pemphigus.  Indian  J  Dermatol  Venereol  Leprol. 2012;78(6):671–676.
35.  Koga H, Tsuruta D, Ohyama B. Desmoglein 3, its pathogenecity and a possibility for therapeutic target in pemphigus vulgaris. Expert Opin Ther Targets. 2013;17(3):293–306.
36.  Lever WF, Schaumburg-Lever G. Treatment of pemphigus vulgaris. Results obtained in 84 patients between 1961 and 1982. Arch. Dermatol. 2014;120(1):44–47.
37.  Meyersburg D, Schmidt E, Kasperkiewicz M, Zillikens D. Immunoadsorption in Dermatology. Ther Apher Dial. 2012;16(4):311–320.
38.  Culton DA, et al. Mucosal pemphigus vulgaris anti-Dsg3 IgG is pathogenic to the oral mucosa of humanized Dsg3 mice. Journal of Investigative Dermatology. 2015;135(6):1590–1597.
39.  Olszewska M, Kolacinska-Strasz Z. Sulej J. Efficacy and safety of cyclophosphamide, azathioprine, and cyclosporine (ciclosporin) as adjuvant drugs in pemphigus vulgaris. Am J Clin Dermatol. 
2007;8(2):85–92.
40.  Brandao ML, Fernandes NC, Batista DP, Santos N. Refractory pemphigus vulgaris associatedwith herpes infection: case report and review. Rev Inst Med Trop Sao Paulo. 2011Mar-Apr; 53(2):113–
117.
41.  Rifaioglu EN, Sen BB, Ekiz O, Dogramaci AC. Mean platelet volume and eosinophilia relationship in patients with bullous pemphigoid. Platelets. 2014;25(4):264–267.
42.  Schiltz JR, Michel B. Production of epidermal acantholysis in normal humanskin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol. 1976;67(2):254–260.
43.  Schmidt E, Zillikens D. The diagnosis and treatmentof autoimmune blistering skin diseases. Dtsch Ärztebl Int. 2011;108:399–405.
44.  Tsang SM, Brown L, Lin K, Liu L, Piper K, O’Toole EA, Grose R, Hart IR, Garrod DR, Fortune F, Wan H. Non-junctional human desmoglein 3 acts as an upstream regulator of Src in E-cadherin adhesion, a pathway possibly involved in the pathogenesis of pemphigus vulgaris. The Journal of Pathology. 
2012. Wiley Online Library// https://onlinelibrary.wiley.com/doi/abs/10.1002/path.3982

•		
Publication of the article	«DERMATOLOGY AND VENEREOLOGY» №4(86), 2019 year, 8-11 pages,
 index UDK 616.527–07–085.357+615.27	
DOI	DOI: 10.33743/2308-1066-2019-4-8-11